Table 3.
Adverse events.
| Parameters | N |
|---|---|
| Stayed on anagrelide treatment | |
| Baseline | 70/70 (100) |
| Week 1 | 69/70 (98.6) |
| Week 4 | 66/70 (94.3) |
| Week 8 | 64/70 (91.4) |
| 6 months | 59/70 (84.3) |
| 12 months | 55/70 (78.6) |
| 24 months | 52/70 (74.3) |
| Medication compliance* | |
| Week 1 | 65/69 (94.2) |
| Week 4 | 63/66 (95.5) |
| Week 8 | 63/64 (98.4) |
| 12 months | 54/55 (98.1) |
| Reasons for anagrelide discontinuation | |
| Adverse events | 7/17 (41.2) |
| Lost to follow-up | 3/17 (17.6) |
| Consent withdrawal | 7/17 (41.2) |
| Symptoms related to anagrelide, any (grade ≥3), events | |
| Headache | 26 (4) |
| Palpitation/chest discomfort | 19 (2) |
| Edem | 17 (4) |
| Generalized weakness/fatigue | 17 (1) |
| Dyspepsia | 12(4) |
| Itching/pruritis | 10(3) |
| Diarrhea/loose stool | 10 (2) |
| Dizziness/light headedness | 10 (0) |
| Epigastric pain | 8 (5) |
| Dyspnea | 7 (1) |
| Abdominal pain | 3 (0) |
| Skin eruption/rash | 5 (1) |
| Bone pain | 5 (1) |
| Anorexia | 5 (2) |
| Constipation | 4 (1) |
| Neuropathy/tingling sensation | 4 (2) |
| Nausea | 3 (1) |
| Uncontrolled blood pressure | 3 (1) |
| Myalgia | 3 (0) |
| Liver function test elevation | 2 (1) |
| Creatinine elevation | 2 (2) |
| Insomnia | 1 (1) |
| Serum glucose elevation | 1 (0) |
*Taken ≥80% of the prescribed drugs.